Post hoc analysis of TOPCAT in 757 HFpEF patients: spironolactone reduced cardiovascular mortality in those with increased left atrial volume index (HR 0.48) and HF hospitalisation in those with increased LV mass index (HR 0.51).
Secondary analysisn = 757
Zang et al. Left Atrial Volume Index and Left Ventricular Mass Index Determine the Benefits of Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction